4.41
-0.25 (-5.37%)
| Previous Close | 4.66 |
| Open | 4.42 |
| Volume | 390,160 |
| Avg. Volume (3M) | 277,368 |
| Market Cap | 248,592,656 |
| Price / Book | 1.02 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -1.68 |
| Total Debt/Equity (MRQ) | 1.68% |
| Current Ratio (MRQ) | 17.49 |
| Operating Cash Flow (TTM) | -81.21 M |
| Levered Free Cash Flow (TTM) | -52.58 M |
| Return on Assets (TTM) | -23.36% |
| Return on Equity (TTM) | -33.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Astria Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | 1.63 |
|
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.47% |
| % Held by Institutions | 104.65% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (Wedbush, 535.64%) | Buy |
| Median | 26.00 (490.24%) | |
| Low | 16.00 (HC Wainwright & Co., 263.22%) | Buy |
| Average | 24.00 (444.84%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 6.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 12 Mar 2025 | 28.00 (535.64%) | Buy | 7.14 |
| HC Wainwright & Co. | 11 Mar 2025 | 16.00 (263.22%) | Buy | 6.47 |
| 27 Feb 2025 | 16.00 (263.22%) | Buy | 6.31 | |
| Citizens Capital Markets | 03 Mar 2025 | 26.00 (490.24%) | Buy | 6.10 |
| JMP Securities | 31 Jan 2025 | 26.00 (490.24%) | Buy | 7.86 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |